VE 16084

Drug Profile

VE 16084

Alternative Names: VE-16,084; VE-16,084 (irreversible peptidyl ICE inhibitor) - Vertex

Latest Information Update: 19 May 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vertex Pharmaceuticals
  • Class Antirheumatics
  • Mechanism of Action Caspase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Rheumatic disorders

Most Recent Events

  • 19 May 2011 Discontinued - Preclinical for Rheumatic disorders in USA (unspecified route)
  • 23 Jul 1998 No-Development-Reported for Rheumatic disorders in USA (Unknown route)
  • 22 Nov 1995 Preclinical development for Rheumatic disorders in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top